v3.26.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Operating Segment (Details)
12 Months Ended
Dec. 31, 2025
USD ($)
segment
Dec. 31, 2024
USD ($)
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES    
Number of reportable segments | segment 1  
Number of operating segments | segment 1  
Total research and development expenses $ 9,802,807 $ 3,602,632
Single reportable segment    
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES    
External clinical development expenses 7,396,788 2,083,119
Personnel related and stock-based compensation 1,532,280 1,073,564
Other research and development expenses 873,739 445,949
Total research and development expenses $ 9,802,807 $ 3,602,632